MA29262B1 - Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 - Google Patents
Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2Info
- Publication number
- MA29262B1 MA29262B1 MA30158A MA30158A MA29262B1 MA 29262 B1 MA29262 B1 MA 29262B1 MA 30158 A MA30158 A MA 30158A MA 30158 A MA30158 A MA 30158A MA 29262 B1 MA29262 B1 MA 29262B1
- Authority
- MA
- Morocco
- Prior art keywords
- diabetes
- prevention
- preparation
- treatment
- rimonabant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UTILISATION DU RIMONABANT SEUL OU ASSOCIÉ À UN AUTRE PRINCIPE ACTIF, POUR LA PRÉPARATION DE MÉDICAMENTS UTILES DANS LA PRÉVENTION ET LE TRAITEMENT DU DIABÈTE DE TYPE 2 OU DIABÈTE NON INSULINO-DÉPENDANT ET/OU DE SES COMPLICATIONS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501861A FR2882261B1 (fr) | 2005-02-21 | 2005-02-21 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
FR0504942A FR2882264A1 (fr) | 2005-02-21 | 2005-05-12 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
FR0505228A FR2882265B1 (fr) | 2005-02-21 | 2005-05-23 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29262B1 true MA29262B1 (fr) | 2008-02-01 |
Family
ID=36809538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30158A MA29262B1 (fr) | 2005-02-21 | 2007-08-23 | Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP2008530189A (fr) |
BR (1) | BRPI0608183A2 (fr) |
CR (1) | CR9293A (fr) |
EA (1) | EA011618B1 (fr) |
FR (2) | FR2882264A1 (fr) |
IL (1) | IL185401A0 (fr) |
MA (1) | MA29262B1 (fr) |
MX (1) | MX2007009996A (fr) |
TN (1) | TNSN07297A1 (fr) |
TW (1) | TW200640457A (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
-
2005
- 2005-05-12 FR FR0504942A patent/FR2882264A1/fr not_active Withdrawn
- 2005-05-23 FR FR0505228A patent/FR2882265B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-20 JP JP2007555669A patent/JP2008530189A/ja not_active Withdrawn
- 2006-02-20 EA EA200701781A patent/EA011618B1/ru not_active IP Right Cessation
- 2006-02-20 MX MX2007009996A patent/MX2007009996A/es not_active Application Discontinuation
- 2006-02-20 BR BRPI0608183-5A patent/BRPI0608183A2/pt not_active IP Right Cessation
- 2006-02-20 TW TW095105631A patent/TW200640457A/zh unknown
-
2007
- 2007-07-31 TN TNP2007000297A patent/TNSN07297A1/en unknown
- 2007-08-07 CR CR9293A patent/CR9293A/es unknown
- 2007-08-20 IL IL185401A patent/IL185401A0/en unknown
- 2007-08-23 MA MA30158A patent/MA29262B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200640457A (en) | 2006-12-01 |
FR2882265B1 (fr) | 2009-02-13 |
EA200701781A1 (ru) | 2007-12-28 |
IL185401A0 (en) | 2008-08-07 |
FR2882264A1 (fr) | 2006-08-25 |
EA011618B1 (ru) | 2009-04-28 |
BRPI0608183A2 (pt) | 2009-11-17 |
JP2008530189A (ja) | 2008-08-07 |
FR2882265A1 (fr) | 2006-08-25 |
MX2007009996A (es) | 2007-10-10 |
CR9293A (es) | 2007-10-01 |
TNSN07297A1 (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1121074A1 (en) | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione | |
BRPI0511477A (pt) | compostos e composições como moduladores de ppar | |
EA200701845A1 (ru) | Рофлумиласт для лечения сахарного диабета | |
NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
HUP0301729A2 (hu) | Gyógyszer szívelégtelenség megelżzésére és kezelésére | |
BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
WO2008028965A3 (fr) | Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications | |
ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
DE602007004615D1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
Schmidinger et al. | Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice | |
WO2006020680A3 (fr) | Composes heterocycliques comme agents pharmaceutiques | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
WO2008149802A1 (fr) | Agent anti-fatigue et composition orale comprenant chacun de l'andrographolide en tant que principe actif | |
DK1680128T3 (da) | Myo-inositolhexaphosphat til topisk anvendelse | |
EP1870099A4 (fr) | Agent protecteur pour une cellule neuronale retinienne comprenant un derive d indazole comme ingredient actif | |
WO2006108681A3 (fr) | Substances et compositions pharmaceutiques pour l'inhibition de glyoxalases et leur utilisation contre des bacteries | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
MA29145B1 (fr) | Préparations pharmaceutiques pour le traitement de la cellulite | |
DK1482919T3 (da) | Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes | |
FR2919187B1 (fr) | Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie. | |
MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
MA29262B1 (fr) | Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |